文献速递核素与放射性配体治疗

基于大颗粒聚合白蛋白的剂量学研究:肝内胆管癌患者接受化疗联合90Y玻璃微球选择性内放射治疗的剂量分析

A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and 90Y-loaded glass microsphere selective internal radiation therapy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-03-20

回顾性分析40例不可手术肝内胆管癌患者,接受90Y玻璃微球选择性内放射治疗联合化疗作为一线治疗,基于大颗粒聚合白蛋白SPECT/CT计算肿瘤剂量、健康注入肝剂量和注入肝剂量。35例可评估患者共55次注射,平均肿瘤剂量322±165Gy,缓解病灶最小肿瘤剂量158Gy,中位无进展生存期12.7个月,中位总生存期28.6个月,Child-Pugh A5患者中位总生存期52.7个月。

要点

  • 联合化疗时,肿瘤剂量>158Gy的90Y玻璃微球选择性内放射治疗高度有效。
  • 6例发生3-4级永久性肝毒性,仅Child-Pugh状态(p=0.0014)和肝硬化(p=0.0021)与肝毒性相关。
  • 中位无进展生存期12.7个月,中位总生存期28.6个月,Child-Pugh A5患者中位总生存期52.7个月。

核心结论

  • 与化疗联合时,90Y玻璃微球选择性内放射治疗高度有效,肿瘤剂量>158Gy;除少数肝硬化或Child-Pugh状态≥A6的患者出现肝毒性外,耐受性良好;需要前瞻性研究确认。

研究设计与样本

  • 回顾性研究,纳入本机构40例接受90Y玻璃微球选择性内放射治疗联合化疗作为一线治疗的不可手术肝内胆管癌患者。
  • 基于大颗粒聚合白蛋白SPECT/CT定量分析计算肿瘤剂量、健康注入肝剂量和注入肝剂量。
  • 治疗后3个月采用欧洲肝病研究协会标准评估缓解,采用单因素分析分析与缓解和毒性相关的因素。

主要发现

  • 共评估35例患者(排除5例),接受55次注射。
  • 平均肿瘤剂量为322±165Gy,平均健康注入肝剂量为74±24Gy,平均注入肝剂量为128±28Gy。
  • 除2个病灶外所有病灶均缓解,缓解病灶的最小肿瘤剂量为158Gy。
  • 观察到6例3-4级永久性肝毒性。
  • 有肝毒性患者平均健康注入肝剂量为73.2±25.8Gy,无肝毒性患者为77.8±16.9Gy,两者无显著关联(ns)。

关键数值与推荐

  • 缓解评估采用欧洲肝病研究协会标准,于治疗后3个月进行。
  • 缓解病灶的最小肿瘤剂量为158Gy。
  • 肝毒性与基础Child-Pugh状态(p=0.0014)和基础肝硬化(p=0.0021)相关。

临床怎么用

  • 作者认为,与化疗联合时,90Y玻璃微球选择性内放射治疗高度有效,肿瘤剂量>158Gy。
  • 作者指出,除少数肝硬化或Child-Pugh状态≥A6的患者出现肝毒性外,耐受性良好。
  • 作者认为需要前瞻性研究确认。

局限性

  • 原文为回顾性研究。
  • 原文结论指出需要前瞻性研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Selective internal radiation therapy (SIRT) appears to be an interesting treatment possibility for locally-advanced intrahepatic cholangiocarcinoma (ICC), yet the appropriate dosimetry has never been evaluated in this context. METHODS: We retrospectively studied data from 40 patients treated at our institution with 90Y-loaded glass microsphere SIRT combined with chemotherapy for inoperable ICC as first-line treatment. Macroaggregated albumin (MAA)-based single-photon emission computed tomography (SPECT)/computed tomography (CT) quantitative analysis was used to calculate the tumor dose (TD), healthy-injected liver dose (HILD), and injected liver dose (ILD). Response was evaluated at 3 months using the European Association for the Study of the Liver criteria. Factors associated with response and toxicity were analyzed using univariate analysis. RESULTS: We assessed a total of 35 patients (five excluded) receiving 55 injections. Mean TD was 322 ± 165Gy and mean HILD was 74 ± 24Gy for a mean ILD of 128 ± 28Gy. All but two lesions responded, with a minimal TD for responding lesions of 158Gy. Six Grade 3-4 permanent liver toxicities were observed. Mean HILD was not associated with liver toxicity (73.2 ± 25.8Gy for patients with liver toxicity and 77.8 ± 16.9Gy for patients without, ns). Only underlying Child-Pugh status (p = 0.0014) and underlying cirrhosis (p = 0.0021) were associated with liver toxicity. Median progression-free survival was 12.7 months and median overall survival (OS) was 28.6 months. Median OS was 52.7 months for patients with Child-Pugh A5 status. CONCLUSIONS: When combined with chemotherapy, SIRT is highly effective, with a TD > 158Gy. Tolerance was good except for the few patients with cirrhosis or Child-Pugh status ≥A6, who exhibited some liver toxicity. Prospective studies are warranted to confirm.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Manceau V, Palard X, Rolland Y, et al. A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and 90Y-loaded glass microsphere selective internal radiation therapy. Eur J Nucl Med Mol Imaging. 2018. PMID: 29560519. doi:10.1007/s00259-018-3990-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。